Ardena acquires CDMO Idifarma, adding spray-drying technology
Ardena, a Belgian pharmaceutical ctract development and manufacturing Organization (CDMO), says it has acquired Idifarma, a Spain-based contract manufacturer of niche and highly potent generic and innovative drugs. Financial terms were not disclosed.
The acquisition from Suanfarma delivers expansion across Southern Europe and supports Ardena’s strategy to become a leading global CDMO, offering integrated solutions across the full pharma development lifecycle.
Idifarma, based in Pamplona, offers a full range of services spanning the pharma lifecycle from formulation, analytical to manufacturing services for highly potent drugs. Its capabilities include a platform for an accelerated path to clinic and innovating spraydrying processes to overcome solubility issues. Established in 2001, and backed by Sodena, Idifarma now has 120 employees.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze